-
3 weeks ago | 
aei.org | Frederick M. Hess |Robert Doar |Benedic Ippolito |Amitabh Chandra
The first 100 days of President Donald Trump’s second term have featured a torrent of education activity. President Trump moved to abolish the US Department of Education, slashing its workforce and yanking hundreds of millions of dollars in grants. He issued executive orders expanding school choice and demanding changes in how institutions manage gender, antisemitism, and diversity, equity, and inclusion.
-
2 months ago | 
aei.org | Amitabh Chandra |Benedic Ippolito |Daniel Cox |Brad Wilcox
Federal policy can significantly alter drugmakers’ incentives, yet there is substantial debate about how various proposals will affect the development of new drugs. At this event, experts will present the latest research on how drug development responds to policy changes—including those introduced by the Inflation Reduction Act—and what that means for coming policy debates.
-
Oct 18, 2024 | 
aei.org | Amitabh Chandra |Pragya Kakani |Michael Kyle |Luca Maini
AbstractMedicare Part D does not allow plans to exclude drugs in six protected classes from their formularies, which may limit plans’ ability to negotiate rebates and lead to higher spending. We estimated the association between protected-class status, US-level estimated rebates, and formulary coverage during the period 2011–19.
-
Aug 8, 2024 | 
aei.org | Amitabh Chandra |John Drum |Michael Daly |Henry Mirsberger
Research and development(R&D)investment in the biopharmaceutical industry drives the discovery of new drugs to address unmet medical needs and improve patient outcomes. Conventional understanding of the magnitude, intensity and productivity of R&D investment in the biopharmaceutical ecosystem is predominantly based on survey data from large, publicly listed biopharmaceutical companies (see Related links).
-
May 6, 2024 | 
aei.org | Amitabh Chandra |Evan Flack |Ziad Obermeyer
AbstractWhat happens when patients suddenly stop their medications? We study the health consequences of drug interruptions caused by large, abrupt, and arbitrary changes in price. Medicare’s prescription drug benefit as-if-randomly assigns 65-year-olds a drug budget as a function of their birth month, beyond which out-of-pocket costs suddenly increase.
-
Mar 5, 2024 | 
aei.org | Amitabh Chandra |Matthew Vogel |Rena Conti
The Inflation Reduction Act (IRA) of 2022 is the most significant reform to US prescription drug pricing in two decades and the first expected to result in a net reduction in Medicare drug costs. Although beneficial for today’s payers and patients, the magnitude of the law’s effect on future innovation is disputed. The Congressional Budget Office (CBO) estimated that the IRA will result in a decrease of one new drug in the first decade and an additional 12 drugs over the following two decades.
-
Mar 5, 2024 | 
healthaffairs.org | Matthew Vogel |Rena Conti |Amitabh Chandra
The Inflation Reduction Act (IRA) of 2022 is the most significant reform to US prescription drug pricing in two decades and the first expected to result in a net reduction in Medicare drug costs. Although beneficial for today’s payers and patients, the magnitude of the law’s effect on future innovation is disputed. The Congressional Budget Office (CBO) estimated that the IRA will result in a decrease of one new drug in the first decade and an additional 12 drugs over the following two decades.
-
Dec 12, 2023 | 
aei.org | Amitabh Chandra |Louis-Jonas Heizlsperger
SummaryTo report employment trends and wages in health care in a systematic way, the authors use data from the Current Employment Statistics program that is administered by the U.S. Bureau of Labor Statistics. The authors review employment, hours, and wages from March 2006 to June 2023, which enables an analysis that places recent trends into perspective in a way that is not possible with only post–Covid-19 pandemic data.
-
Nov 27, 2023 | 
jamanetwork.com | Matthew Vogel |Olivia Zhao |William B. Feldman |Amitabh Chandra
Cost of Exempting Sole Orphan Drugs From Medicare Negotiation Key PointsQuestion What are the costs of the exemption from Medicare price negotiation under the Inflation Reduction Act for drugs approved solely for the treatment of a single rare disease? Findings This cross-sectional study identified 25 “sole orphan” drugs qualifying for exemption from Medicare price negotiation.
-
Nov 8, 2023 | 
aei.org | Amitabh Chandra |Benedic Ippolito |Julia Cataneo
Amitabh Chandra and Benedic IppolitoThe Inflation Reduction Act (IRA) included a host of changes to the way Medicare covers and pays for drugs. In a recent paper, we delved into key policy changes and how they will affect health care delivery. In this piece, we distill three key takeaways for providers and patients to anticipate in the coming years.
